tetano
Editor, Senior Moderator
Int Immunopharmacol. 2018 Aug 3;63:119-128. doi: 10.1016/j.intimp.2018.07.011. [Epub ahead of print]
[h=1]Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.[/h] Liu J[SUP]1[/SUP], Ren Z[SUP]2[/SUP], Wang H[SUP]3[/SUP], Zhao Y[SUP]4[/SUP], Wilker PR[SUP]5[/SUP], Yu Z[SUP]6[/SUP], Sun W[SUP]4[/SUP], Wang T[SUP]4[/SUP], Feng N[SUP]4[/SUP], Li Y[SUP]4[/SUP], Wang H[SUP]4[/SUP], Ji X[SUP]4[/SUP], Li N[SUP]4[/SUP], Yang S[SUP]7[/SUP], He H[SUP]3[/SUP], Qin C[SUP]8[/SUP], Gao Y[SUP]9[/SUP], Xia X[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses cause significant morbidity and mortality and pose a substantial threat to public health. Vaccination represents the principle means of preventing influenza virus infection. Current vaccine approaches are hindered by the need to routinely reformulate vaccine compositions in an effort to account for the progressive antigenic changes that occur as influenza viruses circulate in the human population. In this study, we evaluated chimeric virus-like particle (cVLP) vaccines containing conserved elements of influenza proteins (HL5M2e (HA stem gene with 5M2e gene inserted) and NP), with or without glycosylphosphatidylinositol-anchored CCL28 (GPI-CCL28) and/or GM-CSF (GPI-GM-CSF) fusion proteins as molecular adjuvants. cVLPs elicited strong humoral and cellular immune responses against homologous and heterologous viruses, and improved survival following lethal challenge with both homologous and heterologous viruses. Inclusion of GPI-anchored adjuvants in cVLP vaccines augmented the generation of influenza-specific humoral and cellular immune responses in mice in comparison to the non-adjuvanted cVLP vaccines. VLPs containing GPI-anchored adjuvants reduced morbidity and improved survival to lethal challenge with homologous and heterologous influenza viruses. This work suggests that VLP vaccines incorporating conserved influenza virus proteins and GPI-anchored molecular adjuvants may serve as a platform for a broadly protective "universal" influenza vaccine.
[h=4]KEYWORDS:[/h] Broad-spectrum; GPI-CCL28; GPI-GM-CSF; Influenza cVLPs vaccine; Intranasal administration
PMID: 30081250 DOI: 10.1016/j.intimp.2018.07.011
[h=1]Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.[/h] Liu J[SUP]1[/SUP], Ren Z[SUP]2[/SUP], Wang H[SUP]3[/SUP], Zhao Y[SUP]4[/SUP], Wilker PR[SUP]5[/SUP], Yu Z[SUP]6[/SUP], Sun W[SUP]4[/SUP], Wang T[SUP]4[/SUP], Feng N[SUP]4[/SUP], Li Y[SUP]4[/SUP], Wang H[SUP]4[/SUP], Ji X[SUP]4[/SUP], Li N[SUP]4[/SUP], Yang S[SUP]7[/SUP], He H[SUP]3[/SUP], Qin C[SUP]8[/SUP], Gao Y[SUP]9[/SUP], Xia X[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses cause significant morbidity and mortality and pose a substantial threat to public health. Vaccination represents the principle means of preventing influenza virus infection. Current vaccine approaches are hindered by the need to routinely reformulate vaccine compositions in an effort to account for the progressive antigenic changes that occur as influenza viruses circulate in the human population. In this study, we evaluated chimeric virus-like particle (cVLP) vaccines containing conserved elements of influenza proteins (HL5M2e (HA stem gene with 5M2e gene inserted) and NP), with or without glycosylphosphatidylinositol-anchored CCL28 (GPI-CCL28) and/or GM-CSF (GPI-GM-CSF) fusion proteins as molecular adjuvants. cVLPs elicited strong humoral and cellular immune responses against homologous and heterologous viruses, and improved survival following lethal challenge with both homologous and heterologous viruses. Inclusion of GPI-anchored adjuvants in cVLP vaccines augmented the generation of influenza-specific humoral and cellular immune responses in mice in comparison to the non-adjuvanted cVLP vaccines. VLPs containing GPI-anchored adjuvants reduced morbidity and improved survival to lethal challenge with homologous and heterologous influenza viruses. This work suggests that VLP vaccines incorporating conserved influenza virus proteins and GPI-anchored molecular adjuvants may serve as a platform for a broadly protective "universal" influenza vaccine.
[h=4]KEYWORDS:[/h] Broad-spectrum; GPI-CCL28; GPI-GM-CSF; Influenza cVLPs vaccine; Intranasal administration
PMID: 30081250 DOI: 10.1016/j.intimp.2018.07.011